

Call for Abstracts Instructions

6th World Congress of Cutaneous Lymphomas (6WCCL) June 25–27, 2026 Westin Montréal in Montréal, Canada.

The Scientific Committee invites you to submit abstracts for consideration as oral or poster presentations. Including opportunities for young investigators. Submissions from across the global community of experts are encouraged, with acceptance based on scientific merit. Join us in contributing to a dynamic program that will make this our most impactful Congress yet.

IMPORTANT DATES:

6WCCL Online Abstract System accepts submissions

Thursday, October 16, 2025

Abstract Submission Deadline

Friday, January 23, 2026

Abstract Notification

Tuesday, February 24, 2026

Presenting Author Registration Deadline

Tuesday, March 17, 2026

Presentation at the 6th World Congress of Cutaneous Lymphomas

June 25-27, 2026

Abstract submissions will only be accepted online via the congress online abstract portal. The **submission deadline is January 23, 2026**. Submitting and presenting authors will be required to submit a disclosure statement. A condition of acceptance is that the **presenting author** must register for the conference and be available to present between the dates June 25-27. Confirmation of registration must be received by **March 17, 2026** for the abstract to advance to the Final Program.

PUBLICATION AGREEMENT: Authors of accepted abstracts grant the International Society of Cutaneous Lymphomas (ISCL), its agents and representatives the right to use their names and abstracts in promotional and other materials published in relation to the 6th World Congress of Cutaneous Lymphomas.

AUTHOR ELIGIBILITY: As you prepare for your abstract submission, please note the following eligibility criteria:

- Presenting authors of accepted abstracts (oral or poster) must be present at the Congress, and therefore, must pay the registration fee by the March 17th deadline.

ABSTRACT FORMAT: Abstract submissions will be reviewed for presentation and may be submitted as:

- Oral presentation, *or*
- Poster presentation

Please tick the checkbox if you qualify as a **Young Investigator**: the individual must be an author **and** the presenter, be in a training program and <40 years of age. Young Investigator abstracts will be considered for a special Young Investigators Session.

Please indicate your preferred presentation format. Novel findings must be presented and abstracts previously presented at an International Meeting or published will be disqualified. Please indicate in the online submission form if you will consider a poster presentation in the event your abstract is not selected for oral presentation.



SELECTION PROCESS & TOPICS

All abstracts are subject to an anonymous peer-review by members of the 6th World Congress of Cutaneous Lymphomas Scientific Committee.

Submitting and presenting authors are required to provide a conflict-of-interest disclosure statement. This is required for their abstract to be considered for peer-review, compliance with Canadian CME regulations, and assists in ensuring high-quality, unbiased presentations. Failure to provide a disclosure statement will result in the abstract submission not proceeding to peer-review.

All abstracts submitted must address one of the conference topics for inclusion in the program. When submitting an abstract, please select the topic your abstract applies to from the list below.

- Classification / Epidemiology / Prognostic Factors
- Therapeutics / Preclinical Studies
- Pathology / Biomarkers / microenvironment
- Cutaneous Lymphoma International Consortium – PROCLIP Studies
- Quality of Life / Patient Reported Outcomes
- Challenging Cases of Cutaneous Lymphomas

COMMON REASONS ABSTRACTS ARE REJECTED

- * No learning objectives identified
- * Incomplete disclosure statement
- * Too little data
- * Methods of study not indicated
- * Insignificant study/case
- * Abstract did not conform to guidelines
- * Author or Institution mentioned in body or title
- * Conclusion is questionable in relationship to data presented
- * Abstract is about products or lines of business

NOTIFICATION TIMELINE

Notice of abstract acceptance will be provided **Tuesday, February 24, 2026**. This initial correspondence will be addressed to the **submitting author**. After acceptance, all further correspondence will be directed to the **designated presenting author only**.

Oral presentations will be scheduled during program sessions June 25-27, 2026. Poster presentations will be on display for the duration of the congress. Presenting authors not registered by **Tuesday, March 17, 2026** will forfeit both their invitation to present and inclusion of their abstract in the congress materials.

Oral and Poster Presentation Guidelines will be sent to the registered presenting author on **Friday, May 1, 2026**.



SUBMISSION PROCESS

Abstracts will only be accepted via the [online submission portal](#). Abstracts sent via email, fax or mail will not be accepted. There are no restrictions on the number of abstracts you may submit.

An acknowledgement of receipt of your submission(s) will be sent automatically via email to the submitting author upon successful completion of the online submission. Abstracts will be accepted in English only.

Submitting authors and/or presenting authors may modify their submission(s) until the closing date of **January 23, 2026 at 5:00 PST**. Modifications will not be accepted after the closing date, and late/incomplete submissions will not be accepted.

Abstracts selected for oral or poster presentation at the 6WCCL program will be reproduced exactly as submitted and substitutions/edits will not be permitted. Be sure to proofread your abstract very carefully before completing your submission.

ABSTRACT GUIDELINES

- Prepare your abstract in MS Word. Do not use presentation software (*eg: PowerPoint, Keynote, Google Slides*)
- **Word Limit:** Limit your abstract body to no more than 300 words including references, *not including title or learning objectives*
- **Table or Image:** You may include one (1) graphic or image per submission
- **Learning Objectives:** Include up to three (3) learning objectives. For CME activity, objectives should be clear, concise statements of what the participants should be able to do after your presentation
- **Title:** should be entered in mixed case (upper and lower-case letters) as appropriate. Abbreviations may not be used in the title, unless following the full name
- **Please include co-**authors separately from presenter
- **Disclosure Statement, Conflict-of-Interest Policy:** submitting and presenting authors must disclose any conflicts of interest and acknowledge any support from commercial interests relating to the abstract. They must disclose all relevant financial relationships with an ineligible company (any entity producing, marketing, selling/reselling, or distributing healthcare products used by or on patients) that have occurred within the past 24 months. Authors must agree with the abstract content to be considered for presentation. Identify investigational products or off-label uses of products regulated by the US/Canadian FDA at first mention, and where appropriate in the content, using generic names as opposed to brand/trade names.



Abstract Body to include the following

For Studies:

- Introduction: 2 or 3 brief sentences describing the objectives of the study.
- Methods, Results: this should occupy 1/2 to 2/3 of the abstract, and specific data necessary to evaluate the abstract should be included. If there is concern that additional data would enhance the abstract, please strongly consider including it. Statements such as "data will be discussed at the presentation" are grounds for disqualification.
- Conclusion: 2 or 3 sentences regarding the significance of the results in the context of the original objectives.

For Case Reports:

- Introduction: 2 or 3 brief sentences describing the case's relevance and importance, or what was challenging about it.
- Case Report: the discussion should be no more than 2 or 3 sentences that address why decisions were made and what is interesting/noteworthy about the case. Include lessons learned. Questions to address in the abstract:
 - Why was the study conducted/case reported?
 - How was the study conducted/case reported?
 - What were the results of the study/case?
 - What is the importance of the results?



TRAVEL SCHOLARSHIPS



The ISCL will award travel scholarships to select investigators from under-represented nations (Africa, Asia and Eastern Europe), whose abstract has been accepted for presentation at the congress. Projects that further the aims of the ISCL will be given priority consideration.

ISCL is a non-profit worldwide organization with the aims of:

- Increasing knowledge of lymphoproliferative and related disorders of the skin
- Fostering collaboration among clinicians, scientists and regional or national groups by being sponsor or an international registry of cutaneous lymphomas
- Promoting dissemination of scientific information by organizing meetings
- Favoring consensus about diagnosis, management and treatment of cutaneous lymphomas

Award Details: \$1,000 USD to be distributed at the congress in Canadian dollars to assist with travel costs. A certificate will also be provided. Recipients are required to present their accepted abstract at the 6WCCL and attend the Award Ceremony.

Who Should Apply: Investigators who practice or conduct research in an under-represented nation, and who have submitted an abstract for peer-review consideration. Check the Travel Scholarships box when submitting your abstract if you are interested in applying.

ACCREDITATION

- An accreditation application from the royal College of Physicians and Surgeons of Canada (Section 1 – [Group Learning Activity](#)- is currently in progress for the 6WCCL. Accreditation details, including the number of eligible hours, will be posted on the WCCL website once available.

SUBMIT YOUR ABSTRACT: <https://www.wcclabstracts.com>



Conference Questions?

Conference Secretariat: Annette@simplyeventful.com

Abstract Submission questions?

wccl@scolars.com